Skip to content
NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP

Personalis, Inc. PSNL

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$69.6M
▼ 17.7% YoY
$-81.3M
$-79.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Personalis develops, markets, and sells advanced cancer genomic testing services. We were incorporated under the laws of the state of Delaware in 2011 under the name Personalis, Inc. and became a publicly-traded company in 2019. Our customers include global pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. As of January 31, 2026, we had 260 employees, of which 259 were full-time employees.

Written from the business description in Personalis, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 69.6M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 69.6 · Net income -81.3
30M60M-50M-100M
2017202020232025
Compound annual growth
+2.3%
−2.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −2.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−117 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -126.4% · Net -116.7%
-100%-200%
201720212025
ROE
FY2025 · ROE -35.0%
-20%-40%-60%
201720212025
Three returns, three denominators.

Each USD of equity lost 35 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -79.5
-50M-100M
201720212025

Total assetsUSD 334.2M
EquityUSD 261.2M
CashUSD 124.2M
Current ratio6.76×

Equity funds 78% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PSNL, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.10.10.10.10.10.10.10.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−0.91−1.37−2.25−2.48−1.49−1.20−1.39−6.49−7.78
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−35.0−48.9−62.3−42.9−25.8−27.4———
Shares out B0.100.090.050.050.040.040.030.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image